Melissa Ranjit

TL;DR: In this article, the authors delineate the entire picture of genetic alterations and affected pathways in these glioma types, with sensitive detection of driver genes Grade II and III gliomas comprise three distinct subtypes characterized by discrete sets of mutations and distinct clinical behaviors, suggesting that there is functional interplay between the mutations that drive clonal selection.

TL;DR: It is concluded that glutaminolysis is activated in gliomas with IDH1-R132H mutation and that development of novel therapeutic approaches targeting activated glutaminosynthesis is warranted.

TL;DR: It was concluded that insufficient distribution of cationic liposomes was achieved for tumor treatment by CED, and translation to a clinical setting might be desirable for reinforcing the efficacy of TMZ therapy for GBM.

TL;DR: Recent developments in glioblastoma multiforme (GBM) subtypes, immunohistochemical analyses useful for diagnoses and the biological evaluation and therapeutic implications of gliomas are summarized in this review.

TL;DR: The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in gliomas in routine clinical practice and should help in the differential diagnosis of grade II and III glioma from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue.